Welcome to our dedicated page for Nice SEC filings (Ticker: NCSYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NICE Ltd. filings document the company's foreign-private-issuer reporting through Form 6-K submissions. The records include furnished press releases and exhibits on GAAP financial statements, cloud revenue, AI annual recurring revenue, share repurchases, and financial outlook, with selected financial statements incorporated by reference into Form S-8 registration statements for equity compensation plans.
The filings also record product and customer announcements for NiCE CXone, NiCE Cognigy, and NICE Actimize, including contact-center-as-a-service, AI agents, interaction analytics, fraud detection, financial-crime risk management, and KYC solutions. Governance disclosures cover special general meeting notices, record dates, proxy and electronic voting mechanics, and instructions for American Depositary Share holders.
NICE Ltd. director Zehava Simon filed an initial statement of beneficial ownership, outlining existing holdings in options and ordinary shares. The filing lists multiple option grants over ordinary shares with exercise prices ranging from 0.2657 to 232.2005 and expiration dates between 2026 and 2031. Footnotes state that some stock options are already fully vested and exercisable, while others vest over time, including one grant that vests in three substantially equal installments on March 30, 2026, June 30, 2026 and September 30, 2026. The filing also reports direct ownership of 3,439 ordinary shares, giving investors a clear view of the director’s current equity stake rather than any new transaction.
NICE Ltd. director Dvir Yocheved has reported current equity holdings in a Form 3 insider filing. The disclosure lists multiple stock option awards over NICE ordinary shares with exercise prices ranging from 0.2929 to 232.2005 and expiration dates between 2026 and 2031. The filing also shows direct ownership of 395 NICE ordinary shares. Footnotes explain that some options are already fully vested and exercisable, while others will vest in installments through specific dates in 2026.
NICE Ltd. executive Udi Yehuda Dayan, VP of Corporate Finance, filed an initial insider report listing existing stock option holdings in the company’s Ordinary Shares. The filing shows options over 750 Ordinary Shares at an exercise price of 0.3060 expiring on March 14, 2028, and 3,000 Ordinary Shares at an exercise price of 0.3134 expiring on December 23, 2031, among other grants. Footnotes explain that some options are already vested and exercisable, while others will vest in scheduled installments through 2030. No new purchases or sales are reported; this Form 3 simply establishes Dayan’s existing option positions.
NICE Ltd. executive vice president of human resources Neder Shiri reported existing holdings of stock options on the company’s Ordinary Shares. The awards have exercise prices ranging from 0.2706 to 0.3228 and individual grants covering 1,200 to 12,500 underlying shares, with expirations between March 3, 2027 and February 18, 2033.
Footnotes explain that several options are already vested and exercisable, while others vest over future dates in 2027, 2028 and 2029. One performance-based grant is eligible to vest over a three-year performance period ending February 18, 2029, depending on specified stock price thresholds.
NICE Ltd. Chief Executive Officer Russell Scott Edward reported his initial ownership in the company. He directly holds 65,989 Ordinary Shares and has Performance Share Units linked to 27,500 underlying Ordinary Shares.
Footnotes add that his equity awards include 33,000 restricted stock units and 16,500 performance stock units, each representing a contingent right to receive one Ordinary Share, vesting under their award terms. Certain performance share units are eligible to vest over a three-year period ending January 1, 2028 based on specified stock price performance thresholds.
NICE Ltd. director Ben-Shaoul Rimon filed an initial Form 3 reporting his equity holdings in the company. He directly owns 995 Ordinary Shares and a series of employee stock options over additional Ordinary Shares with varying exercise prices and expiration dates.
These options include grants exercisable for 3,980 shares at an exercise price of 151.6300 per share expiring on April 30, 2026, and others such as 2,785 shares at 224.1800 per share expiring on September 10, 2026. Footnotes state that some options are fully vested and currently exercisable, while others vest in installments through September 30, 2026.
NICE Ltd. director Leo Apotheker filed an initial ownership report showing multiple stock option grants over Ordinary Shares. The options cover various underlying share amounts with exercise prices such as 224.1800 and 144.9030 and expiration dates from 2026 through 2031, with some already fully vested and others vesting through September 30, 2026.
NICE Ltd. director Joseph Lamar Cowan filed an initial Form 3 detailing his equity stake in the company. He reports direct ownership of 4,769 Ordinary Shares, which includes 746 restricted stock units that vest under the terms of their awards, each representing one Ordinary Share.
Cowan also reports indirect ownership of 11,183 Ordinary Shares held by a corporation, and several option grants over Ordinary Shares. These stock options carry exercise prices ranging from $144.9030 to $232.2005 per share and expire between April 2026 and September 2031, with some fully vested and others scheduled to vest in installments during 2026.
NICE Ltd. director David Kostman filed an initial Form 3 reporting his beneficial ownership. He directly holds 19,146 Ordinary Shares, which include 1,744 RSUs and 7,635 ADRs, each ADR representing one Ordinary Share. He also reports multiple option awards over Ordinary Shares, such as options exercisable for 14,920 shares at an exercise price of $151.63 expiring on April 30, 2026 and options for 10,423 shares at $224.18 expiring on September 10, 2026, along with additional grants extending through 2031. The filing records current holdings and does not show new purchases or sales.
NICE Ltd. filed an initial Form 3 for director Dan Michael Falk, detailing his existing stock option holdings in the company’s ordinary shares. The filing lists multiple option awards with different exercise prices and expiration dates ranging from 2026 through 2031.
Some options, including grants covering ordinary shares at exercise prices such as 224.1800 and 144.9030, are fully vested and currently exercisable. One grant is already exercisable for 746 ordinary shares and is scheduled to vest in three substantially equal installments on March 30, 2026, June 30, 2026, and September 30, 2026. Another option grant will fully vest on September 30, 2026. The form records holdings only and does not report new purchases or sales.